About Us

Members of the Intervention Insights team discuss how to create better solutions for molecular oncology.

About us

We believe in doing what’s right for the patient. That means bringing molecular medicine to routine clinical care: evidence-based, efficiently administered and keeping pace with the speed of science.

Management Team

We are business and health professionals with deep healthcare industry experience, leveraging our diverse areas of expertise to continuously improve Intervention Insights solutions and the future of molecular oncology.

Clynt Taylor
Chief Executive Officer
Clynt Taylor - Chief Executive Officer

Mr. Taylor is the Chief Executive Officer of Intervention Insights and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.

Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth - including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions. Clynt is married with four children and lives in the Dallas area.

Russell Ingersoll, PhD
Chief Product Officer
Russell Ingersoll, PhD - Chief Executive Officer

Mr. Ingersoll joined Intervention Insights in August, 2010, bringing 15 years of healthcare information technology experience and proven success with the design and commercialization of information-based technology products for the clinical and life science industries.

Prior to joining Intervention Insights, Mr. Ingersoll served as VP of Product Development for MedTrust Online, an oncology-centric information portal; Senior Director of Business Development at Phylogeny, Inc., a functional genomics services company; co-Founder of Folio Biosciences, a biobank of clinically annotated specimens and co-founder of BioProtocol, an interactive laboratory protocol system for the research community.

Mr. Ingersoll received a BS in Molecular and Cellular Biology from the University of Arizona, a PhD in Pharmacology and Toxicology from the University of Arizona College of Pharmacy and completed his post-doctoral training at the University of California, Berkeley.

Ephraim Hochberg, MD
Chairman, Editorial Board & Sr. Clinical Advisor
Ephraim Hochberg, MD – Senior Clinical Advisor

Dr. Hochberg serves as a Senior Clinical Advisor and Chairman of the Editorial Board of Intervention Insights. Dr. Hochberg received his MD from Case Western Reserve University School of Medicine, Ohio in 1996. He completed an internship and residency at Brigham and Women’s Hospital, followed by a fellowship at the Dana Farber Cancer Institute. Dr. Hochberg is an Assistant Professor of Medicine at Harvard Medical School and is an attending physician at the Massachusetts General Hospital. He serves as the Clinical Director of Inpatient Oncology at the Massachusetts General Hospital Cancer Center.

With over 50 peer-reviewed publications and book chapters, he directs his research efforts towards novel therapies for Hodgkin and non-Hodgkin lymphomas. Additionally, he is a member of the NCCN Guideline Panel for Hodgkin Lymphoma.

Janine Morales, PhD
Director of Clinical Knowledge Management
Janine Morales, PhD – Director of Clinical Knowledge Management

Ms. Morales joined the Intervention Insights team in 2011 and oversees a team of editors and curators with deep expertise in molecular oncology. Her group is responsible for maintaining the company’s clinical information asset, a comprehensive knowledgebase summarizing published data pertaining to molecular biomarkers as predictors of response to targeted therapies in oncology. Ms. Morales also led the development of Intervention Insights’ framework for the systematic evaluation and synthesis of molecular clinical evidence as well as the principles guiding the presentation of molecular evidence in patient specific reports.

She brings 15 years of editorial and information management experience in the biotech and medical sectors and was a member of research and development teams at Elan Corp. and DNAX Research Institute (acquired by Merck & Co).

Ms. Morales received a BS in Biochemistry from the University of Rochester and earned her PhD in Pharmacology from the University of California, San Francisco.

Board of Directors

Providing strategic guidance to support the growth and success of Intervention Insights.

Wright Steenrod
Director
Wright Steenrod, Director

Mr. Steenrod joined Chrysalis as an Associate in 2001 and today leads the Technology Group. Bringing his own entrepreneurial management experiences to the Chrysalis team, Wright previously worked as a senior business development executive at a rapidly growing company preparing to go public, and served as CFO of a start-up technology transfer company where he set strategic plans and raised equity and debt capital. Wright has worked with the management teams of fourteen of Chrysalis’ investments including Digitalsmiths (sold to TiVo), Advanced Academics (sold to DeVry), Genscape (sold to GFI) and Appriss (sold to Bain Capital), in the Technology portfolio among others. He currently is a Director of Cybera, Regent Education, Straighterline, Xlerant and meQuilibrium.

From 1995 to 1998, Wright worked at SunTrust Bank in Atlanta as an Associate in Mergers and Acquisitions. Prior to SunTrust, he served five years in the US Marine Corps where he attained the rank of Captain.

Wright has a BA in Economics from Princeton University.

A Louisville native, Wright is active in the community working with organizations such as the Boys and Girls Clubs of Kentuckiana and Kentuckiana Works.

Michael Gross
Director
Michael Gross, Director

Mr. Gross is responsible for investment sourcing, deal execution and portfolio management, specifically for the InvestMichigan! Growth Capital Fund. He focuses on the healthcare and medical technology sectors and has expertise in medical devices, diagnostics, life science research, drug delivery, healthcare providers and outsourced services. Mr. Gross serves as a board director for Beringea portfolio companies Molecular Imaging, gloStream, Delphinus Medical Technologies, InTouch Health, Intervention Insights and Relume Technologies and is a board observer for Pioneer Surgical Technology and MedVantx.

Prior to joining Beringea, Mr. Gross was a Vice President of investment banking with P&M Corporate Finance (PMCF). While at PMCF, he led M&A transactions and capital raises for companies in the life sciences, healthcare and outsourced business services sectors.

Before working at PMCF, Mr. Gross worked in the investment banking group at Stout Risius Ross, Inc. He is a CFA charterholder and earned a BA in Finance from Michigan State University.

Clynt Taylor
Director & CEO
Clynt Taylor, Director & CEO

Mr. Taylor is the Chief Executive Officer of Intervention Insights and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.

Since beginning his career at IBM, he’s held leadership roles at healthcare technology companies like NextGen, where he led sales and marketing teams; HealthVision as General Manager of its fastest growing division (purchased by Lawson) and Galvanon as Co-founder and CEO Healthcare Solutions (purchased by NCR). Most recently, he held various senior executive roles with NantHealth - including leading the innovation, launch and commercialization of eviti, Inc., recognized today as one of the nation’s premier oncology decision support solutions. Clynt is married with four children and lives in the Dallas area.

Mark Olesnavage
Observer
Mark Olesnavage, Observer

Mr. Olesnavage has led Hopen Life Sciences since 2006. A veteran of the pharmaceutical and nutraceutical industries, he has held senior management positions in business divisions in the United States, Europe and the Pacific Rim. He spent 24 years with Perrigo Company, where he held various senior management positions, including Executive Vice President and General Manager. During his tenure, he was involved in several key acquisitions and saw the company’s sales grow from $70 million to $1.3 billion (in 2005). Mr. Olesnavage also was a driver in the development of numerous product and technology partnerships. He was previously a longtime member of the Generic Pharmaceutical Association and the Consumer Healthcare Products Association and has served on the executive committee of both groups. Prior to Perrigo, he held international marketing positions with Amway Corp.

Charlie Crawford
Observer
Charlie Crawford, Observer

Mr. Crawford is an Associate at Chrysalis Ventures. He works with the management teams of existing Chrysalis investments across the firm’s focus areas of healthcare and technology and is currently a Director of Chrysalis’ portfolio company, NextImage Medical. Mr. Crawford is also actively involved in identifying new investment opportunities for Chrysalis.

Prior to Chrysalis, Mr. Crawford worked as a Senior Analyst at Innova Memphis, a Tennessee-based venture capital firm, where he was involved in the firm’s investments in healthcare services, technology and medical devices.

Mr. Crawford received his BA with Honors from Williams College.

Editorial Board

Subject matter experts committed to ensuring the accuracy and reliability of Intervention Insights solutions.

Ephraim Hochberg, MD
Mass General Hospital, Harvard Medical School

Dr. Hochberg serves as a Senior Clinical Advisor and Chairman of the Editorial Board of Intervention Insights. Dr. Hochberg received his MD from Case Western Reserve University School of Medicine, Ohio in 1996. He completed an internship and residency at Brigham and Women’s Hospital, followed by a fellowship at the Dana Farber Cancer Institute. Dr. Hochberg is an Assistant Professor of Medicine at Harvard Medical School and is an attending physician at the Massachusetts General Hospital. He serves as the Clinical Director of Inpatient Oncology at the Massachusetts General Hospital Cancer Center.

With over 50 peer-reviewed publications and book chapters, he directs his research efforts towards novel therapies for Hodgkin and non-Hodgkin lymphomas. Additionally, he is a member of the NCCN Guideline Panel for Hodgkin Lymphoma.

Alice Shaw, MD, PhD
Mass General Hospital,
Harvard Medical School

Dr. Shaw is an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, an assistant professor of medicine at Harvard Medical School and a clinical investigator at MIT's Koch Institute for Integrative Cancer Research. In addition to caring for patients with lung cancer, she performs clinical and translational research.

Dr. Shaw's major research interests include studying anaplastic lymphoma kinase (ALK) translocations in non-small cell lung carcinoma (NSCLS), developing targeted strategies to treat NSCLCs harboring activating KRAS mutations, discovering new targets in NSCLC using both genetic and phosphoproteomic strategies and developing novel nanoparticle-based siRNA delivery systems to target genetically defined subsets of lung cancer. Dr Shaw has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the Burroughs Welcome Fund, the V Foundation for Cancer Research and the NIH/NCI.

Aditya Bardia, MBBS, MPH
Mass General Hospital,
Harvard Medical School

Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. He is the recipient of the Young Investigator Award from the ASCO Conquer Cancer Foundation.

Wolfram Goessling, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School

Dr. Goessling is a Professor of Medicine and of Health Sciences and Technology at Harvard Medical School. He received his MD and doctorate from the University of Witten/Herdecke in Germany. He trained in Internal Medicine at Brigham and Women's Hospital, served as Chief Medical Resident, and completed fellowship training in Hematology/Oncology at the combined Dana-Farber/Partners program and in Gastroenterology at Massachusetts General Hospital. Dr. Goessling pursued his postdoctoral research with Dr. Leonard Zon at Children’s Hospital, using zebrafish to characterize regulators of liver development, regeneration and cancer. He sees patients with liver disease and liver cancer at Dana-Farber Cancer Institute and Brigham and Women’s Hospital.

Paul A. Bunn, Jr., MD
University of Colorado Cancer Center

Dr. Bunn is the James Dudley Professor of Lung Cancer Research at the University of Colorado and Executive Director of the International Association for the Study of Lung Cancer (IASIC). He was Director of the University of Colorado Cancer Center from 1986-2009.

Dr. Bunn is an internationally recognized oncologist with notable professional distinctions including Past President of ASCO, IASLC and AACI, as well as serving as chairman of the FDA Oncology Drug Advisory Committee. As principal investigator, he has provided specific elucidation of the etiology, natural history and molecular markers important for diagnosis, prognosis and optimization of therapeutic choice to tailor personalized care. These findings have carried over to the direction of numerous clinical trials and the administration of the SPORE translational research grant in lung cancer.

In addition to his clinical duties, he has published more than 300 peer-reviewed articles and over 90 book chapters in peer-reviewed journals including Journal of Thoracic Oncology, Journal of Clinical Oncology and Clinical Cancer Research. He continues to work on numerous regional and national cancer research projects.

Harriet M. Kluger, MD
Yale University Cancer Center

Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drugs and biomarkers predictive of response to these drugs in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumors and cells from patients treated with novel therapies.

Anna F. Farago, MD, PhD
Mass General Hospital,
Harvard Medical School

Dr. Farago is an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, an instructor at Harvard Medical School, and a research affiliate at the Koch Institute for Integrative Cancer Research at MIT. Dr. Farago cares for patients with lung cancer and other thoracic malignancies, and also performs clinical and translational research.

Dr. Farago's major research interests include studying small cell lung cancer (SCLC) and other lung neuroendocrine cancers. She works with preclinical models including genetically engineered mouse models of SCLC in the laboratory of Dr. Tyler Jacks at MIT's Koch Institute for Integrative Cancer Research. She also works to develop new preclinical models of SCLC and performs research through clinical trials. Dr. Farago has been awarded several research grants, including grants from Uniting Against Lung Cancer and the Conquer Cancer Foundation of ASCO/AACR.

Scientific Advisory Board

A team of recognized thought leaders in the field of molecular oncology.

Stanley R. Hamilton, MD
MD Andersen Cancer Center

Dr. Hamilton was awarded his MD in 1973 from the Indiana University School of Medicine in Indianapolis. He completed his internship and Residency in Pathology and Laboratory Medicine at Johns Hopkins University School of Medicine and Hospital in Baltimore, Maryland.

Dr. Hamilton currently is Professor and Head of the Division of Pathology & Laboratory Medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas and holds the Frederick F. Becker Distinguished University Chairman in Cancer Research. Prior to arriving at the M.D. Anderson Cancer Center in 1998, he was a Professor at Johns Hopkins University School of Medicine and Hospital in Baltimore, Maryland.

Dr. Hamilton is board certified in Anatomic and Clinical Pathology. His laboratory research activities focus on two main areas of translational applications to the management of patients with GI cancer; identification and application of molecular markers for prognosis of gastrointestinal adenocarcinomas and for prediction of response to therapy and the etiology and molecular pathogenesis of colorectal neoplasia. He is a Gastrointestinal Pathologist with clinical and research interests in the molecular genetics and genomics of colorectal neoplasia. In addition to his clinical and academic duties, Dr. Hamilton has served as the PI for multiple studies and has published numerous peer-reviewed articles and book chapters.

Paul A. Bunn, Jr., MD
University of Colorado Cancer Center

Dr. Bunn is the James Dudley Professor of Lung Cancer Research at the University of Colorado and Executive Director of the International Association for the Study of Lung Cancer (IASIC). He was Director of the University of Colorado Cancer Center from 1986-2009.

Dr. Bunn is an internationally recognized oncologist with notable professional distinctions including Past President of ASCO, IASLC and AACI, as well as serving as chairman of the FDA Oncology Drug Advisory Committee. As principal investigator, he has provided specific elucidation of the etiology, natural history and molecular markers important for diagnosis, prognosis and optimization of therapeutic choice to tailor personalized care. These findings have carried over to the direction of numerous clinical trials and the administration of the SPORE translational research grant in lung cancer.

In addition to his clinical duties, he has published more than 300 peer-reviewed articles and over 90 book chapters in peer-reviewed journals including Journal of Thoracic Oncology, Journal of Clinical Oncology and Clinical Cancer Research. He continues to work on numerous regional and national cancer research projects.

W. Jeffrey Edenfield, MD
Institute for Translational Oncology Research

Dr. Edenfield earned his MD from the University of Miami, Florida. He completed his internship, residency and fellowship at Walter Reed Army Medical Center in Washington, DC. Dr. Edenfield also completed a research fellowship in Hematologic Malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He recently completed his active duty service obligation as Chief of Oncology at Womack Army Medical Center in North Carolina where he was awarded an Army Commendation Medal as well as the Womack Army Medical Center Teacher of the Year Award. Dr. Edenfield is board certified in Medical Oncology, Hematology and Internal Medicine.

Dr. Edenfield received his certification in Hospice and Palliative Medicine in February, 2006. Hospice and Palliative Medicine is the medical discipline of care devoted to achieving the best possible quality of life for patients and their families throughout the course of life-threatening illnesses through the relief of suffering and the control of symptoms.

In addition to his clinical duties, Dr. Edenfield has published numerous peer-reviewed articles. He is a member of the American College of Physicians and the American Society of Clinical Oncology.

Investors